BioSpace News Archive

Bluestar Genomics announces today it received U.S. Food and Drug Administration (FDA) Breakthrough Device designation for its proprietary noninvasive pancreatic cancer detection test in patients with new-onset diabetes.

Researchers at Beaumont Health have used precision medicine to discover a simple blood test that may provide an early prediction of Alzheimer’s disease in patients, according to a study published today.

Piramal Pharma Limited’s Contract Development and Manufacturing Organization, Piramal Pharma Solutions, announced that PPL has entered into an agreement to acquire a 100% stake in Hemmo Pharmaceuticals Pvt Ltd. for an upfront consideration of INR 775 crores and earn-outs linked to achievement of milestones.

Apotex Corp is voluntarily recalling three lots of Guanfacine Extended-Release Tablets 2mg to the consumer level due to trace amounts of Quetiapine Fumarate in one lot RX1663.

Bioasis Technologies Inc., a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, is pleased to announce that it has formed a research collaboration with Aposense Limited.

Dr. Reece led the UMSOM through Period of Unprecedented Growth Across All Mission Areas; He Will Return to the UMSOM Faculty to Lead a New Center, and Continue Research and Teaching

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, reported financial results for the full year 2020 and provided an update on recent business highlights.

BioXcel Therapeutics, Inc. announced topline results from its Phase 1b/2 proof-of-concept RELEASE study of BXCL501, the Company’s proprietary, orally dissolving thin film formulation of dexmedetomidine, for the treatment of opioid withdrawal symptoms.

Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and twelve months ended December 31, 2020.

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced receipt of U.S. Food and Drug Administration (“FDA”) approval for the new Inspire physician programmer platform